Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1 alpha level. (C) 2013 Elsevier Ireland Ltd. All rights reserved.